anoth cf triplerx combo begin phase trial crispr option
orkambi sale million beat million estim total
billion kalydeco sale million also beat
million estim total million vertex provid cf sale
guidanc non-gaap dilut ep vertex end
cash billion remain confid tezacaftor/ivacaftor approv
homozyg residu function patient februari pdufa date
importantli vertex select advanc phase triplerx
trial addit vertex exercis option crispr crsp beta
thalassemia sickl cell diseas scd potenti first-in-man data year
reiter overweight rate increas target
increas price-to-earnings multipl prior due acceler growth triplerx regimen
anoth strong quarter orkambi sale million beat
million estim driven uptak younger cf children total billion
kalydeco sale million also beat million estim due
sale residu function patient total million vertex provid
cf sale guidanc non-gaap dilut ep
tez/iva approv come remain confid tez/iva approv homozyg
residu function cf patient februari pdufa date
europ upon approv anticip residu function patient simpli
add tezacaftor kalydeco monotherapi expect exist orkambi new
homozyg function patient transit start tez/iva
gate mutat patient remain kalydeco monotherapi
triplerx phase trial start importantli vertex select two next-gen corrector
advanc phase triplerx trial homozyg
heterozyg patient vertex plan first initi two phase trial combin
tez/iva upon addit phase ii data vertex expect intiat phase
trial tezacaftor concert once-daili potenti
believ vertex least one year ahead competit ultim anticip
patient consolid onto triplerx
crispr data come vertex exercis option therapi
treat beta thalassemia sickl cell diseas crispr file cta
beta thal intend file ind scd soon first ever
potenti cur data could driver share year vertex
crispr co-develop co-commerci
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
thru
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
thousand except per share data
good sold
royalti payment
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found
